Nuvation Bio Inc NUVB Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Cui Xiangmin

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

4,183,002

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Cui Xiangmin

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,675,236

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Cui Xiangmin

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

314,106

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Sjogren Colleen

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

250,000

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Sjogren Colleen

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

500,000

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Wang Junyuan Jerry

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

388,299

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Wang Junyuan Jerry

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

486,669

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Wang Junyuan Jerry

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

550,758

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Wang Junyuan Jerry

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,378,989

Price:

--
Apr 02, 2024 (filed on Apr 02, 2024)

Insider Name:

Sjogren Colleen

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--

Filings by filing date

Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Cui Xiangmin

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

4,183,002

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Cui Xiangmin

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,675,236

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Cui Xiangmin

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

314,106

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Sjogren Colleen

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

250,000

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Sjogren Colleen

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

500,000

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Wang Junyuan Jerry

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

388,299

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Wang Junyuan Jerry

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

486,669

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Wang Junyuan Jerry

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

550,758

Price:

--
Apr 09, 2024 (filed on Apr 11, 2024)

Insider Name:

Wang Junyuan Jerry

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,378,989

Price:

--
Apr 02, 2024 (filed on Apr 02, 2024)

Insider Name:

Sjogren Colleen

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	357 Tehama Street, Floor 3 SAN FRANCISCO CA 94103
Tel:	1-212-6001902
Website:	https://www.nuvationbio.com
IR:	See website

Key People

David T. Hung President, Chief Executive Officer, Founder, Director	Moses Makunje Principal Accounting Officer, Principal Financial Officer	Stacy Markel Chief People Officer
Gary Hattersley Chief Scientific Officer	David Hanley Chief Technical Operations Officer	David Liu Chief Medical Officer
Colleen Sjogren Chief Commercial Officer	Kerry A. Wentworth Chief Regulatory Officer

Business Overview

Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.

Financial Overview

For the fiscal year ended 31 December 2023, Nuvation Bio Inc revenues was not reported. Net loss decreased 27% to $75.8M. Lower net loss reflects Interest income increase from $7.4M to $24.6M (income), Research & Development Expensd decrease of 16% to $62.5M (expense), General and administrative expenses ds decrease of 18% to $17.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.48 to -$0.35.

Employees:	51 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$25.25M as of Dec 31, 2023
Annual revenue (TTM):	$0.00M as of Dec 31, 2023
EBITDA (TTM):	-$99.60M as of Dec 31, 2023
Net annual income (TTM):	-$75.80M as of Dec 31, 2023
Free cash flow (TTM):	-$68.07M as of Dec 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	246,692,474 as of Apr 9, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization